Testing for thrombophilia: An evidence-based approach

Postgraduate Medical Journal

Volumn 82, Issue 973, 2006, Pages 699-704

  Merriman, L ^a   Greaves, M ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; BLOOD EXAMINATION; FEMALE; HUMAN; MASS SCREENING; METHODOLOGY; MYELOPROLIFERATIVE DISORDER; NEOPLASM; ORGANIZATION AND MANAGEMENT; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; THROMBOPHILIA;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEMATOLOGIC TESTS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MASS SCREENING; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA;

EID: 34648847176     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2006.048090     Document Type: Review

References (42)

1. Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haematol 2001;114:512-28.
2. Hettiarachchi RJ, Lok J, Prins MH, et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998;83:180-5.
3. Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004;2:884-9.
4. Lensing AW, Prandoni P, Prins MH, et al. Deep-vein thrombosis. Lancet 1999;353:479-85.
5. Samuelsson E, Hagg S. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand 2004;83:674-81.
6. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997;78:1183-8.
7. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-16.
8. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-4.
9. Martinelli I, Bucciarelli P, Margaglione M, et al. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111:1223-9.
10. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005;3:459-64.
11. Heit JA, Sobell JL, Li H, et al. The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort study. J Thromb Haemost 2005;3:305-11.
12. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombi n and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-80.
13. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20.
14. Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996;125:955- 60.
15. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996;16:742-8.
16. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
17. Pabinger I, Nemes L, Rintelen C, et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000;1 :37-41.
18. Martinelli I, Legnani C, Bucciarelli P, et al. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-3.
19. Middeldorp S, Libourel EJ, Hamulyak K, et al. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001;113:553-5.
20. Tirado I, Mateo J, Soria JM, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005;93:468-74.
21. Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-63.
22. Baglin T, Luddington R, Brown K, et al. High risk of recurrent venous thromboembolism in men. J Thromb Haemost 2004;2:2152-5.
23. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-61.
24. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6.
25. Eichinger S, Weltermann A, Mannhalter C, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002;162:2357-60.
26. Mansilha A, Araujo F, Severo M, et al. Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study. Eur J Vasc Endovasc Surg 2005;30:545-9.
27. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001;113:630-5.
28. Rintelen C, Pabinger I, Knobl P, et al. Probabil ity of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996;75:229-32.
29. Procare G. Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients? Blood Coagul Fibrinolysis 2003;14:523-9.
30. van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997;157:2227-32.
31. Wu O, Robertson L, Twaddle S, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis, Br J Haematol 2005;131:80-90.
32. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999;72:646-51.
33. Lensen RP, Bertina RM, de Ronde H, et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000;83:817-21.
34. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52.
35. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80.
36. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25.
37. Hoibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
38. Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32.
39. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000;343:1439-44.
40. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005;3:949-54.
41. Favaloro EJ. Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process. Semin Thromb Hemost 2005;31 :85-9.
42. Hellmann EA, LeslieND, Moll S. Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost 2003;1 :2335-9.